To allow us to manage our work programme and ensure we are providing guidance close to the point of marketing authorisation, we have taken the decision to move the first committee meeting discussion of maribavir to later in 2022. Therefore, the discussion of maribavir on 7 July 2022 has been cancelled and will be rescheduled to 7 September 2022.